Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)
Assess the safety and efficacy of 9MW2821 in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who have previously failed to intravesical therapy. Provide a new treatment option for patients with NMIBC recurrence, reduce the risk of tumor recurrence, decrease the rate of radical bladder surgery, and enhance the quality of life for patients.
Bladder Cancer
DRUG: 9MW2821
Safety and tolerability, assess the incidence of AE/SAE, up to 12 months|RP2D and MTD, Determine the recommended phase 2 dose (RP2D) and the maximum tolerated dose (MTD) that may occur., up to 12 months
DFS rate of 12 months, Disease-free survival rate of 12 months, Up to 12 months|DoR of CR, Duration of complete response, Up to 20 months|CR rate of 3/6/12 months, Complete response rate of 3/6/12 months, Up to 12 months|DFS, Disease-free survival, Up to 20 months|Duration to radical cystectomy, Duration to radical cystectomy, Up to 20 months|Proportion of radical cystectomy, Proportion of radical cystectomy, Up to 20 months|Biomarker parameter, Expression of Nectin-4, Up to 20 months
Assess the safety and efficacy of 9MW2821 in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who have previously failed to intravesical therapy. Provide a new treatment option for patients with NMIBC recurrence, reduce the risk of tumor recurrence, decrease the rate of radical bladder surgery, and enhance the quality of life for patients.